Cellectar Biosc Cmn (CLRB) 2.74 $CLRB Cellectar

New Post Public Reply Private Reply Replies (0) Message Board

Sep 25, 2016 at 5:07 PM

Cellectar Biosc Cmn (CLRB) 2.74 $CLRB

Cellectar Biosciences To Present at OktoberINVESTfest
GlobeNewswire - Wed Sep 21, 7:30AM CDT
Cellectar Biosciences, Inc. (Nasdaq:CLRB) (the "company"

, an oncology-focused biotechnology company, today announces that Jim Caruso, president and CEO of Cellectar, will present at the OktoberINVESTfest presented by Joseph Gunnar & Co. on September 28, 2016.
CLRB: 2.74 (-0.04)

Cellectar Biosciences to Present at Ladenburg Thalmann 2016 Healthcare Conference
GlobeNewswire - Mon Sep 19, 7:30AM CDT
Cellectar Biosciences, Inc. (Nasdaq:CLRB) (the "company"

, an oncology-focused biotechnology company, today announces that Jim Caruso, president and CEO of Cellectar, will present at the Ladenburg Thalmann 2016 Healthcare Conference on September 27, 2016, which will be held at the Sofitel Hotel at 45 West 44 Street in New York City.
CLRB: 2.74 (-0.04)

Cellectar Biosciences Announces Lead Compound CLR 131 To Be Studied In Head and Neck Cancer in $12M University of Wisconsin SPORE Grant
GlobeNewswire - Mon Sep 12, 7:30AM CDT
Cellectar Biosciences, Inc. (Nasdaq:CLRB) ("the company"

, an oncology-focused biotechnology company, today announces that its lead therapeutic compound, CLR 131, currently in a Phase 1 clinical trial for multiple myeloma and preparing for a Phase 2 study in multiple myeloma and other hematologic malignancies, will be evaluated by the University of Wisconsin in combination with external beam radiation as a potential combination treatment for head and neck cancers (squamous cell carcinoma). The research will be conducted as part of a Specialized Program of Research Excellence (SPORE) grant, awarded to the University of Wisconsin by the National Cancer Institute.
CLRB: 2.74 (-0.04)

Cellectar Biosciences To Present at the 18th Annual Rodman & Renshaw Global Investment Conference
GlobeNewswire - Tue Sep 06, 7:30AM CDT
Cellectar Biosciences, Inc. (Nasdaq:CLRB) (the "company"

, an oncology-focused biotechnology company, today announces that Jim Caruso, CEO of Cellectar, will present at the 18 Annual Rodman & Renshaw Global Investment Conference being held at the Lotte New York Palace Hotel from September 11-13, 2016.
CLRB: 2.74 (-0.04)

Cellectar Biosciences Announces Recent Key Accomplishments and Second Quarter 2016 Financial Results
GlobeNewswire - Thu Aug 11, 3:45PM CDT
Cellectar Biosciences, Inc. (Nasdaq:CLRB) ("the company"

, an oncology-focused biotechnology company, today announces key accomplishments and its financial results for the second quarter of 2016, which ended June 30, 2016.
CLRB: 2.74 (-0.04)

Medical Product Stock Earnings Coming Up: IMMY, OMCM, CLRB
Zacks Equity Research - Zacks Investment Research - Thu Aug 11, 6:50AM CDT
For the rest of the season, earnings are anticipated to grow 4.7%, driven by impressive top-line growth expectation of 7.7% in Medical sector.
CLRB: 2.74 (-0.04), IMMY: 3.82 (-0.05)

Technical Roundup on Biotech Stocks -- Juno Therapeutics, Cellectar Biosciences, Titan Pharma, and Rexahn Pharma
PR Newswire - Tue Aug 09, 8:43AM CDT
Sentiments over the Biotech industry have improved in previous weeks on confidence over drug pipelines and better global conditions. However, stocks are still down 13% this year. Today, Stock-Callers.com reviews four names to see how they have performed recently: Juno Therapeutics Inc. (NASDAQ: JUNO), Cellectar Biosciences Inc. (NASDAQ: CLRB), Titan Pharmaceuticals Inc. (NASDAQ: TTNP), and Rexahn Pharmaceuticals Inc. (NYSE MKT: RNN). Sign up today and download for free the research reports for the stocks covered today at:
CLRB: 2.74 (-0.04), RNN: 0.22 (unch), TTNP: 6.01 (-0.05), JUNO: 30.11 (-0.51)

Cellectar Biosciences to Host Conference Call on August 15 to Report Second Quarter 2016 Financial Results and Corporate Performance
GlobeNewswire - Mon Aug 08, 7:30AM CDT
Cellectar Biosciences, Inc. (Nasdaq:CLRB), ("the company"

, an oncology-focused biotechnology company, today announces that management will host a teleconference and live webcast to report second quarter 2016 financial results followed by a review of corporate performance, on August 15, 2016 at 8:30 AM EDT.
CLRB: 2.74 (-0.04)

Cellectar Biosciences Announces $2 Million NCI SBIR Contract for a Phase 2 Clinical Study
GlobeNewswire - Wed Aug 03, 7:00AM CDT
Cellectar Biosciences, Inc. (Nasdaq:CLRB) ("the company"

, an oncology-focused biotechnology company, today announced that it has received the second phase of a National Cancer Institute ("NCI"

Fast-Track Small Business Innovation Research ("SBIR"

contract award in the amount of $2 million to support funding of a Phase 2 clinical study of the company's lead product candidate, CLR 131, for the potential treatment of hematologic malignancies, including multiple myeloma.
CLRB: 2.74 (-0.04)

These Stocks Are Making Big Moves
ACCESSWIRE - Fri Jun 03, 8:15AM CDT
NEW YORK, NY / ACCESSWIRE / June 3, 2016 / Small caps have been having an explosive week thus far. In this article we take a look at three small cap stocks that have been moving substantially higher over the last few trading sessions.
CLRB: 2.74 (-0.04)

Cellectar Biosciences to Present at the LD Micro Invitational
ACCESSWIRE - Thu Jun 02, 7:30AM CDT
MADISON, WI and LOS ANGELES, CA / ACCESSWIRE / June 2, 2016 / Cellectar Biosciences (Nasdaq: CLRB), an oncology-focused biotechnology company, today announced that it will be presenting at the 6th annual LD Micro Invitational on Thursday, June 9 at 9:30 AM PST/12:30 PM EST. Jim Caruso, president and CEO of Cellectar, will present the company and meet with investors.
CLRB: 2.74 (-0.04)

Cellectar Biosciences Announces USPTO Issues Patent for its Radiotherapeutic PDC Portfolio, Further Strengthening and Expanding Protection for Its Delivery Platform
GlobeNewswire - Tue May 31, 7:30AM CDT
Cellectar Biosciences, Inc. (Nasdaq:CLRB) ("the company"

, an oncology-focused biotechnology company, today announces that the United States Patent and Trademark Office ("USPTO"

has issued U.S. Patent No. 9,339,564, which covers the treatment of cancer stem cells employing the company's phospholipid drug conjugate ("PDC"

delivery platform technology; specifically, either of the company's current PDC products, CLR 131 or CLR 125, in combination with external beam radiation. This patent, which provides intellectual property protection to at least June 2030, is based on one of multiple patent applications directed to the treatment of cancer stem cells.
CLRB: 2.74 (-0.04)

Cellectar Biosciences Announces USPTO Issues Patent for New Phospholipid Drug Conjugate (PDC) with Paclitaxel
GlobeNewswire - Wed May 25, 7:30AM CDT
Cellectar Biosciences, Inc. (Nasdaq:CLRB) ("the Company"

, an oncology-focused biotechnology company, today announces that the United States Patent and Trademark Office has issued U.S. Patent No. 9,345,718 on May 24, 2016, which covers CLR 1603, a phospholipid ether-paclitaxel conjugate.
CLRB: 2.74 (-0.04)

Cellectar Biosciences to Present at the 5th Annual SeeThru Equity Microcap Investor Conference
GlobeNewswire - Tue May 24, 7:30AM CDT
Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused biotechnology company, announces today its CEO, Jim Caruso, will be presenting at the 5 Annual SeeThru Equity Microcap Investor Conference on Tuesday, May 31, 2016 at 11:00 AM ET. The conference is being held at Convene, which is located at 730 Third Avenue in New York City.
CLRB: 2.74 (-0.04)

4 Small Cap Stocks That Traders Can't Get Enough of Today
ACCESSWIRE - Mon May 23, 2:01PM CDT
NEW YORK, NY / ACCESSWIRE / May 23, 2016 / The Stock Expert is issuing a report on four stocks that are performing well today. XNPT, CLRB, BBEP and XGTI are on high volume alert. Continue reading to find out why. - To get daily alerts on the hottest stocks on the Nasdaq/NYSE subscribe to our newsletter at TheStockExpert.com.
CLRB: 2.74 (-0.04), BBEP: 0.13 (unch), XGTI: 0.29 (-0.01), XNPT: 7.07 (+0.05)

Cellectar Biosciences to Present at the 2016 Marcum MicroCap Conference
GlobeNewswire - Mon May 23, 7:30AM CDT
Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused biotechnology company, announces today its CEO, Jim Caruso, will be presenting at the 2016 Marcum MicroCap Conference at the Grand Hyatt in New York City on June 2, 2016 at 3:30 PM ET in the Julliard Room.
CLRB: 2.74 (-0.04)

These 4 Stocks Are Taking Advantage of Today's Market Rally
ACCESSWIRE - Fri May 20, 12:12PM CDT
CORAL GABLES, FL / ACCESSWIRE / May 20, 2016 / TechStockInsider.com issues the following report: Today Wall Street rose after retreating earlier in the week on renewed concerns the U.S. Fed would raise interest rates in the near-term. Worldwide stock markets appear to have dismissed remarks from New York Fed President William Dudley on May 19 that bolstered rumors that a Fed rate rise might be on the table in June. This prompted major U.S. stock indexes to close lower yesterday.
CLRB: 2.74 (-0.04), ORIG: 0.77 (-0.03), GLBS: 0.70 (+0.01)

Cellectar Biosciences Patent Application for Phospholipid-Ether Analogs as Cancer Targeting Drug Vehicles Published by USPTO
GlobeNewswire - Fri May 20, 7:30AM CDT
Cellectar Biosciences, Inc. (NASDAQ:CLRB) (the Company), an oncology-focused biotechnology company, today announces that its previously filed non-provisional US and International (PCT) patent applications for Phospholipid-Ether Analogs as Cancer Targeting Drug Vehicles have received their US Patent and Trademark Office (USPTO) identification numbers and have been published by the USPTO, which marks the next step in the application process for approval and issuance of these patents.
CLRB: 2.74 (-0.04)

Cellectar Biosciences Announces First Quarter 2016 Financial Results
GlobeNewswire - Thu May 12, 3:15PM CDT
Cellectar Biosciences, Inc. (NASDAQ:CLRB), an oncology-focused biotechnology company, today announces its financial results for the first quarter of 2016.
CLRB: 2.74 (-0.04)

Cellectar Biosciences to Host Conference Call on May 12, 2016 to Report First Quarter 2016 Financial Results and Provide a Corporate Performance Update
GlobeNewswire - Wed May 04, 7:30AM CDT
Cellectar Biosciences, Inc. (NASDAQ:CLRB), an oncology-focused biotechnology company, today announces that management will host a teleconference and live webcast to report first quarter 2016 financial results, followed by a review of corporate performance, on May 12 at 5:00 PM EDT.
CLRB: 2.74 (-0.04)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Adam Foundation's Ramadan Effort to Cut Plastic Waste

Environmental Consciousness: A Call from Antalya Here we go again, folks. Something refreshing is brewing over in Antalya at COP31, where the UK-based Adam Foundation has made a move that resonates beyond the usual hubbub. No smoke and mirrors, just straightforward action aimed at cutting down the wave of plastic waste during Ramadan. This isn't some pie-in-the-sky green...

Positron AI's Strategic Moves Garner Top Recognition

Breaking Barriers in AI Hardware When a tech firm starts making waves in the AI sphere, ears perk up. Positron AI, with its focus on making AI inference not only feasible but profitable and scalable, finds itself freshly minted on the esteemed 2026 AI 100 list. This isn’t just a little pat on the back; it's a nod from the industry's watchful gaze. Momentum Backed by...

CytoSorbents Hits Financial Milestone in Q3 2026

CytoSorbents' Financial Turnaround Imagine the smell of fresh opportunity wafting through CytoSorbents’ (NASDAQ:CTSO) corridors this quarter. The company just nudged into positive territory with its operating cash flow, which, let’s be honest, is like finding a nugget of gold amid last year’s rubble of losses. With $43,000 of positive operating cash flow in a world...

FDA Greenlights AI for Brain Aneurysm Detection

Unveiling UPTUNITY: A New AI Solution Well, ain't that something? Bracco and Avicenna.AI just got the FDA's nod for their latest creation, UPTUNITY. It's like giving radiologists a trusty sidekick to spot those sneaky brain aneurysms. This ain't just another gizmo; it's a game-changer in medical imaging, giving AI a real shot at transforming how these medical sleuths do...

NJ Water Boosts Fire & EMS Grants to $5K in 2027

Water Utility Backs First Responders with Bigger Bucks Listen up, folks. The New Jersey American Water company just threw down the gauntlet with some bold moves for its 2027 Volunteer Fire and EMS Grant Program. They've taken the maximum grant amount from $2,500 to $5,000. Yeah, you heard right. Doubling the pot and starting the application cycle earlier means volunteer...

Veterans Guardian Earns 2026 Gold HIRE Vets Medallion

Veterans Guardian Celebrates Another Milestone Alright, folks, let me hit you with a piece of news that didn't just skim across the ticker like another stock price—this one's truly for the soul. Veterans Guardian VA Claim Consulting out of Pinehurst, North Carolina, snagged the 2026 Gold HIRE Vets Medallion Award from the U.S. Department of Labor. It's a nod that goes...

Zinzino's 2027 Nomination Committee Prepares for AGM

Unveiling Zinzino's New Nomination Committee Ah, Gothenburg—the city known for its beautiful canals and now, yet another lineup change for Zinzino AB's Nomination Committee. This is part and parcel of the games companies play before their Annual General Meetings (AGM) and generally an indicator of either stasis or shifts ahead. The names on the roster for Zinzino’s...

Avoid Costly Checking Account Mistakes: Key Tips

Oversights That Could Drain Your Wallet Let me tell you, folks skip over their checking account details like it's a doctor's recommended veggie list. Even seasoned bankers trip up on the regular. Banking Expert Trent Nelson of PriorityOne Bank spills the beans on how understanding your account could save you from costly missteps and keep unnecessary fees at bay. Turns...

Pet Supplies Plus Celebrates Success in Customer Service

Acknowledging Excellence in Retail Service You don't often see a pet store at the top of such elite lists, but Pet Supplies Plus has managed exactly that. Ranked number one in its category for both customer service and franchise performance, they've set a benchmark others ought to take note of. We’re talking number 41 on Forbes' Best Customer Service list and number 51...

Newsday Unveils Essential Guide to NY Colleges

Launching a Comprehensive College Resource Ah, the college decision stress. Back in the day it was simpler, just pick a campus that looked good on paper and hope for the best. But now? Kids and their families have got a minefield of information to navigate. Time to make room at the table for Newsday's latest attempt to unravel the college chaos with their Essential Guide...